JT Receives Manufacturing and Marketing Approval of ENAROY® Tablets 2 mg・4 mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan
(WorldNews Japan)

FOR IMMEDIATE RELEASE Tokyo, September 25, 2020 JT Receives Manufacturing and Marketing Approval of ENAROY® Tablets 2 mg･4 mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced that JT has today received manufacturing and marketing approval for ENAROY® Tablet 2 mg and 4 mg (generic name: enarodustat) (hereinafter "ENAROY®"), a hypoxia inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for an indication of anemia associated with chronic kidney disease (CKD) in Japan. ENAROY® is an orally-activeHIF-PH inhibitor that...